Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions are filled with praise and anticipation for lenacapavir's role in HIV prevention, exemplified by phrases like 'game-changer', 'zero infections', and 'fantastic new tool', illustrating excitement through positive tone, detailed references, and strong emphasis on the treatment's potential to transform HIV prevention efforts.
Most discussions express strong support and optimism about the study results, emphasizing the high efficacy of lenacapavir in preventing HIV among women.
The posts show a very high level of interest, citing detailed results, studies, and potential clinical impacts with enthusiasm.
Participants reference specific data, trial outcomes, and express excitement, indicating deep engagement with the research and its implications.
Many discussions highlight the potential for significant public health benefits, such as nearly 100% prevention efficacy and FDA approval, underscoring high impact.
5 medical breakthroughs from June (
Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZpszL Editorial: The Real PURPOSE of PrEP — Effectiveness, Not Efficacy https://t.co/8pbyZQ7uB3 #AIDS2024 | @iasociety https://t.co/WC6fT2lduC
2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100% efficacy in the first and 99.9% efficacy in the second Approval: https://t.co/Jb2fpDyunX Trial: https://t.co/pQC2b0zaUA https://t.co/yKr03xjiVj
@ladyfromk Ну по перше це ж PrEP, тому тут питання велике в вірусному навантаженні проте це дослідження 3 фази, тому пару років і буде https://t.co/1SvEIAZwgV
Son günlerde sosyal medyada çok tartışıldı. ❓HİV aşısı bulundu mu? ❓HİV’den %100 korunmak mümkün mü? ❓HİV tarihin tozlu sayfalarına mı gömülüyor? Gelin beraberce bu tartışmalara nokta koyalım ve çok önemli bir tedaviyi öğrenelim. https://t.co/XQvrnmP4CH https://t.co/ZSWpfHQPam
Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2. Lenacapavir >95% efficacy for HIV prevention (trial 2) https://t.co/HDEy4HO3pl 3. Video from the AIDS conference, 2024 https://t.co/rTf7BeiHU3 4. Details on
This phase 3 trial evaluated twice-yearly lenacapavir and daily F/TAF for HIV prevention among young women in South Africa and Uganda. Lenacapavir was highly effective with no HIV cases detected, demonstrating its…
This phase 3 trial demonstrates that twice-yearly Lenacapavir effectively prevents HIV in adolescent girls and young women, with no HIV cases in the Lenacapavir group, showing its strong potential as a prevention…
HIV hakkında her şey. This phase 3 trial tests twice-yearly Lenacapavir and daily F/TAF in preventing HIV among young women in South Africa and Uganda, showing Lenacapavir's high effectiveness with no HIV cases in that…
This phase 3 trial evaluated the efficacy of twice-yearly Lenacapavir and daily F/TAF in preventing HIV among adolescent girls and women in South Africa and Uganda. Results show Lenacapavir's high effectiveness, with no…
This phase 3 trial demonstrates that twice-yearly lenacapavir effectively prevents HIV in adolescent girls and young women, showing no HIV cases in the group. It offers a promising alternative to daily PrEP with high…
Recent scientific focus has turned to Lenacapavir, an injectable medication that can prevent HIV for up to 6 months with a single dose. This review discusses its mechanism, study results, and potential impact on global…
Lenacapavir, a new long-acting HIV prevention drug, requires only two injections per year, effectively protecting against HIV for up to six months. In this video, we explore its efficacy compared to daily PrEP and…
This phase 3 trial evaluated twice-yearly Lenacapavir and daily F/TAF for HIV prevention in young women, showing Lenacapavir's high effectiveness with no HIV cases in that group, outperforming background infection rates.
A revolutionary study demonstrates that twice-yearly lenacapavir injections provide 100 protection against new HIV infections, showing promising results in clinical trials and potential for significant public health…
This phase 3 trial evaluated lenacapavir's effectiveness as a twice-yearly injection for HIV prevention in adolescent girls and young women, with no HIV cases observed among those receiving lenacapavir, demonstrating…
The PURPOSE 1 study evaluated twice-yearly lenacapavir and daily F/TAF for HIV prevention in women, showing high effectiveness of lenacapavir with no HIV cases in the group. The study was published in the New England…
@moneyacademyKE It is promising given that its Phase 3 showed good results (0 HIV infections in the 2,134 people who received lenacapavir twice yearly) : https://t.co/GOmMI6Znj1
These data come from the first phase 3 trial (https://t.co/pQC2b0zIK8) And here's the second one (https://t.co/HDEy4HOBeT)
Two trials on lenacapravir for prevention of HIV https://t.co/fl2U2x1kVr https://t.co/5j1XB1UEJj Two trials on high dose influenza vaccine https://t.co/U7gfJaTvGP https://t.co/UxF3IboPJV https://t.co/xOGj6AGDcX
@LaCienegaBlvdss I’ve been following Lenacapavir for a min. There’s another one for cis women and how it is safe for pregnancy. I’ll link you too. https://t.co/AuRLwXGHL1
Relire les deux études PURPOSE Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women www.nejm.org/doi/10.1056/...
A large efficacy trial in African adolescent girls & young women reporting that lenacapavir reduces HIV infections to zero (NEJM, free with registered account)
Adding some additional info, two trial arms published (3 more to come I believe): zero (ZERO!!!) seroconversion in 2,138 participants. Articles are not open access. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women www.nejm.org/doi/full/10....
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
تزریق دوبار در سال لناکاپاویر ۱۰۰ درصد از ابتلا به اچ آی وی در زنان با وضعیت پرخطر پیشگیری کرد. آدرس کارآزمایی purpose1 https://t.co/klxP2AxTgB در جمعیت ۵۰۰۰ نفری زنان در معرض خطر اچ آی وی تزریقات انجام شد و آمار ابتلا به اچ آی وی صفر بوده است.https://t.co/42ZAseEuti
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
Clinical Pearls based on the landmark NEJM study: “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” (PURPOSE 1 Trial)
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine. https://t.co/acOv7ijzIC
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
RT @DrSamuelBHume: 5 medical breakthroughs from June (
5 medical breakthroughs from June (
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
В первом исследовании участвовали 5338 девушек из ЮАР и Уганды. В группе lenacapavir не заразился ни один человек. В контрольных группах — 55 заражений. Исследование было двойным слепым: и инъекции, и таблетки были с плацебо — чтобы всё было честно: https://t.co/aWUKHr3YhM
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
RT @DrSamuelBHume: 2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100…
2. Lenacapavir - a twice-yearly HIV preventative - approved by the FDA It's been tested in two phase 3 trials, with 100% efficacy in the first and 99.9% efficacy in the second Approval: https://t.co/Jb2fpDyunX Trial: https://t.co/pQC2b0zaUA https://t.co/yKr03xjiVj
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
I dati dei trials più importanti: https://t.co/t3vO4b8gr6 https://t.co/RvzL6xCC91 https://t.co/DPzxvP0ZCI https://t.co/GPgApUVMxu https://t.co/iqvwca0mSD
@ne_zhdu_ @swantz48 Возможно, возможно (!) он может иметь эффективность и при уже имеющемся вич+ статусе, но это пока никак не проверяли https://t.co/lapQAlurcl https://t.co/QrT6x1gGrw Тут про механизм действия и исследование само
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
@davidbautistaqf https://t.co/z8EOSOXnsw
Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2. Lenacapavir >95% efficacy for HIV prevention (trial 2) https://t.co/HDEy4HO3pl 3. Video from the AIDS conference, 2024 https://t.co/rTf7BeiHU3 4. Details on
RT @DrSamuelBHume: @DrDominicNg Agreed I am excited about this for HIV prevention - the FDA decision on approval is coming up in June ht…
@DrDominicNg Agreed I am excited about this for HIV prevention - the FDA decision on approval is coming up in June https://t.co/YHV1xnc4YZ https://t.co/50UZFyhNHW
9️⃣ Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
For the ladies https://t.co/5UXZ9kUk4T
RT @DrSamuelBHume: Sources: 1. https://t.co/Y0Raog12xk 2. https://t.co/YHV1xnc4YZ 3. Many RCTs
RT @DrSamuelBHume: Sources: 1. https://t.co/Y0Raog12xk 2. https://t.co/YHV1xnc4YZ 3. Many RCTs
RT @DrSamuelBHume: Sources: 1. https://t.co/Y0Raog12xk 2. https://t.co/YHV1xnc4YZ 3. Many RCTs
Sources: 1. https://t.co/Y0Raog12xk 2. https://t.co/YHV1xnc4YZ 3. Many RCTs
7️⃣ Profilaxis DOXICICLINA y vacuna Meningococo B en ITS
九つ目。Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region https://t.co/2L7uI8yLOh
８つではレナカパビルのprep、年２回の注射で済むのはコンプライアンスあがりますね。 Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/2L7uI8yLOh
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/dH92mpyQ5k
RT @docramiro: Profilaxis VIH con Lenacapavir. Efectividad del 100% en mujeres. Referencia: 10.1056/NEJMoa2407001 https://t.co/9fA25qUQua
https://t.co/RZBO6WMoVM
RT @SamuelBHume: Source for original post: https://t.co/3MCHuATE4P And here's the study on Lenacapavir for HIV prevention: https://t.co/pQ…
RT @doctormacias: Lenacapavir, inyección dos veces al año. Fármacos como éste podrían lograr la eliminación de las infecciones por VIH en p…
Sources HIV prevention in women: https://t.co/YHV1xnc4YZ HIV prevention in men: https://t.co/HDEy4HO3pl
RT @docramiro: Profilaxis VIH con Lenacapavir. Efectividad del 100% en mujeres. Referencia: 10.1056/NEJMoa2407001 https://t.co/9fA25qUQua
Another insanity. A trial based on cisgender. The mere fact that this trial used the word cisgender and that they scouted for women who call themselves cis says a lot about what is behind this particular trial. https://t.co/g3FkuUj4mg
RT @GrupoAF_VIH_SEF: Hoy traemos un hilo sobre el empleo de lenacapavir (LEN) vs emtricitabina tenofovir alafenamida (F/TAF) para la preven…
Hoy traemos un hilo sobre el empleo de lenacapavir (LEN) vs emtricitabina tenofovir alafenamida (F/TAF) para la prevención del VIH en mujeres cisgénero. El artículo ha sido publicado en The NEW ENGLAND JOURNAL of MEDICINE. https://t.co/XQ1OktlBUS #ProfilaxisPreExposición #VIH
RT @nidanuki: そういえば去年だったな、学会で新薬が完全に感染を抑え込んだ報告に拍手が湧いたって話を見たけど、HIV治療の実際って此処まで来たんだって改めて思ったんだよな。 この人がちゃんと治療に繋がって、自分らしく生きていける事を RT https://t.co…
RT @nidanuki: そういえば去年だったな、学会で新薬が完全に感染を抑え込んだ報告に拍手が湧いたって話を見たけど、HIV治療の実際って此処まで来たんだって改めて思ったんだよな。 この人がちゃんと治療に繋がって、自分らしく生きていける事を RT https://t.co…
そういえば去年だったな、学会で新薬が完全に感染を抑え込んだ報告に拍手が湧いたって話を見たけど、HIV治療の実際って此処まで来たんだって改めて思ったんだよな。 この人がちゃんと治療に繋がって、自分らしく生きていける事を RT https://t.co/S3FbV8vl31
In the PURPOSE 1 randomized, controlled trial involving women in South Africa & Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection. Full trial results: nej.md/3zRElVj #MedSky #IDSky
esta nueva ataca a una proteína de su cápside, evitando que pueda entrar al núcleo de las células. 3.Además, el PrEP generalmente es tomado en pastillas, lo cuál puede generar fallas en el tratamiento pues hay personas que olvidan tomarlas. https://t.co/VbxngXkpiI
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
生命科学VTuberが選ぶ生命科学2024年10大ニュース #たかとー研究室 https://t.co/H6wd7uQHEV @YouTubeより
RT @takatoh_life: (私見で選ぶ)生命科学2024年10大ニュース #たかとー研究室 https://t.co/hvCxUkx4ut
RT @takatoh_life: (私見で選ぶ)生命科学2024年10大ニュース #たかとー研究室 https://t.co/hvCxUkx4ut
RT @takatoh_life: (私見で選ぶ)生命科学2024年10大ニュース #たかとー研究室 https://t.co/hvCxUkx4ut
(私見で選ぶ)生命科学2024年10大ニュース #たかとー研究室 https://t.co/hvCxUkx4ut
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
論文はこれらしい。 https://t.co/n3GsN0TD6A 正確には治験対象者は、5338人。 https://t.co/NFHWFnj8a4
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
แต่ก็ยังไม่เห็นมีใครพูดถึงเรื่องยารักษาHIVที่แน่นอน มีแต่ยาป้องกันล่าสุดที่อัพเดท ที่สามารถป้องกันได้ถึง 96% https://t.co/dXYibf9DDc
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
¡Novedades sanitarias de 2024! Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/YdUBeyMNLh
RT @DrAkhilX: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/iZQbhntubJ https://t.co/E5Y5HJaG…
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Women. Overall Survival with Pembrolizumab in Early-Stage Triple -ve Br CA
RT @DrAkhilX: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/iZQbhntubJ https://t.co/E5Y5HJaG…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/iZQbhntubJ https://t.co/E5Y5HJaGFD
https://t.co/ukMJhS2iea ข่าวสำหรับเข้า h
ขอส่งข่าวร ปีใหม่คิดใช้2570 https://t.co/ukMJhS2iea
RT @ativittta: Son günlerde sosyal medyada çok tartışıldı. ❓HİV aşısı bulundu mu? ❓HİV’den %100 korunmak mümkün mü? ❓HİV tarihin tozlu sayf…
Son günlerde sosyal medyada çok tartışıldı. ❓HİV aşısı bulundu mu? ❓HİV’den %100 korunmak mümkün mü? ❓HİV tarihin tozlu sayfalarına mı gömülüyor? Gelin beraberce bu tartışmalara nokta koyalım ve çok önemli bir tedaviyi öğrenelim. https://t.co/XQvrnmP4CH https://t.co/ZSWpfHQPam
https://t.co/E9JuUOHjqi
https://t.co/230Je6jknJ
@ladyfromk Ну по перше це ж PrEP, тому тут питання велике в вірусному навантаженні проте це дослідження 3 фази, тому пару років і буде https://t.co/1SvEIAZwgV
In case you missed it: “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women”. No infections in the Lenacapavir arm. #Wow https://t.co/4kqHOsXsZ3
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women 南アフリカとウガンダで、シスジェンダー女性におけるHIV予防効果を評価するため、年2回の皮下注射レナカパビルと、毎日経口投与されるF/TAFおよびF/TDFを比較する第3相ランダム化比較試験が実施された。 https://t.co/Wa6FMNb5Fm
The paper on lencapavir in "NEJM" “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” 2/3 https://t.co/T9NbmGneYI
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/ID76b1EXgW
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/eiLSYmuHbD
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZpszL Editorial: The Real PURPOSE of PrEP — Effectiveness, Not Efficacy https://t.co/8pbyZQ7uB3 #IDTwitter https://t.co/D5ZK47OoCB
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/F5uCjxnhiv
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @SamuelBHume: Source for original post: https://t.co/3MCHuATE4P And here's the study on Lenacapavir for HIV prevention: https://t.co/pQ…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/4VN0m3hoD6
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/0KlNgsjq63
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
RT @gorka_orive: ¡Grandísima noticia! Presentados en un congreso sobre SIDA los datos con el fármaco Lenacapavir que previene el 100% de la…
A new first-class ATR demonstrated zero infections after two years of use in preventing HIV among adolescent girls and young women in Uganda and South Africa. The primary results were published here: https://t.co/nXHs2OnjPR https://t.co/RwRpP9zeNP
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
@CougarSpider and especially especially now that lenacapavir has been shown to be ~100% effective at preventing HIV infection with two shots a year. already FDA approved as a treatment for existing patients, so there's nothing stopping it from being used immediately. https://t.co/1AOn7p37Oa
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women（シスジェンダー女性の HIV 予防のための年 2 回のレナカパビルまたは毎日の F/TAF） www.nejm.org/doi/10.1056/... 「南アフリカとウガンダの思春期の少女と若い女性を対象に、第3相二重盲検ランダム化比較試験を実施」 レナカパビルを年2回投与された参加者でHIV感染なし(100人年あたり0件)。
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/MV2eOA0DRE
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/nWqDV3MPIA
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/pauIvCg181
ICYMI
RT @annetkiraboc1: Fantastic paper led by @fmatovu2 “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” is now…
RT @annetkiraboc1: Fantastic paper led by @fmatovu2 “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” is now…
Fantastic paper led by @fmatovu2 “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” is now published in New England Journal of Medicine! https://t.co/N3B9pL6zyj
RT @NICU_doc_salone: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine….This…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine….This trial of a twice yearly pre-exposure prophylaxis injection for adolescent girls and women at high risk for HIV is very impressive https://t.co/HOzBLSrx6C
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/sIMVSGCzAH
『大きく前進か！？HIV曝露前予防（PrEP）』 Bekker L-G, Das M, Karim QA, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med 2024 Jul 24. doi: 10.1056/NEJMoa2407001.： https://t.co/M0CKoPekFg
Wow, that went well...Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/tL3YxX0tmB
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/Y0kiLTAHzU
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/0sSOpEcH0I
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women #science #publication #research #publications https://t.co/cE25mwNkHq
【RCT】若い女性へのLenacapavirの投与は、エムトリシタビン・テノホビル ジソプロキシルフマル酸塩の投与と比較して、HIVの発生率を低下させた。エムトリシタビン・テノホビル アラフェナミドフマル酸塩とは差がなかった。 #ペ読 https://t.co/ZLQ51xaXka
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. @morgfair https://t.co/RfnTCe8TB8
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. https://t.co/J2vZQX2EnO
"Twice-yearly lenacapavir: a game-changer in HIV prevention for cisgender women!
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender women No participants receiving twice-yearly lenacapavir acquired HIV infection. www.nejm.org/doi/ful... 2/3
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/bFYmYr3hBC
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/Vx9E7EmKyL wow wow wow!
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine (https://t.co/qsOHllGT8I)
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/uYHJYtg5NA
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/iFOrpzgbiU
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/0sSOpEcH0I
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
The PROMISE-1 results are amazing. ZERO new HIV infections in the arm of the twice a year injectable PrEP
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
RT @kajiru: Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine h…
Significant. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/xypqbcZjxU
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Fantastic new tool to prevent the spread of HIV! Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/7dpspDrTIr
RT @YvesGebhardt: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women #AIDS2024 Via @c_gaebler Excellent news!…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/gkT1mPwfgF
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @YvesGebhardt: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women #AIDS2024 Via @c_gaebler Excellent news!…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…
Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZpszL Editorial: The Real PURPOSE of PrEP — Effectiveness, Not Efficacy https://t.co/8pbyZQ7uB3 #AIDS2024 | @iasociety https://t.co/WC6fT2lduC
RT @YvesGebhardt: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women #AIDS2024 Via @c_gaebler Excellent news!…
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women @NEJM @drmoupali https://t.co/3eFTJkMN3o
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | New England Journal of Medicine https://t.co/BwUZIFP5Oh
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women #AIDS2024 Via @c_gaebler Excellent news! Thank you @c_gaebler for sharing! @MARTHOLANAH @Flatmi @6dm4 @defeatHIV @RaifDerrazi @ProfSharonLewin @iasociety https://t.co/KR5XxqJf2q
RT @metodologica_cl:
RT @metodologica_cl:
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women https://t.co/hpBfc0RPsd
RT @metodologica_cl:
RT @metodologica_cl:
ACCP HIV PRN. 520 likes. The HIV PRN offers members the opportunity to collaborate and discuss the management of patients with HIV through transitions of...
Dr H Ismail – Co-Investigator. Publications. Published 24 July 2024:Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med . 2024;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. OpenUrl ...
3. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women | NEJM. PURPOSE 1 RCT: No participants receiving twice-yearly lenacapavir ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. New England Journal of Medicine. 2024; in press. Gilead Sciences. Gilead's ...
Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults; Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women ...
... HIV can be prevented with a twice-yearly antiviral injection (3). ... Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women.
Twice-yearly lenacapavir or daily f/taf for HIV prevention in cisgender women. . N. Engl. J. Med. 391::1179–92. [Google Scholar]. 22. Landovitz R, Donnell D ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in. Cisgender Women. L.-G. Bekker, M. Das, Q. Abdool Karim, K. Ahmed, J. Batting, W. Brumskine, K ...
Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024. Available at: https ...
Article and Study Summary: Article Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women Published in: N Engl J Med. 2024;391(13):1179– ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024; 391:1179-1192. Google Scholar. 3. Kelley, CF ∙ Acevedo ...
... lenacapavir and emtricitabine/tenofovir alafenamide for PrEP. See the Gilead statement. on global access planning for lenacapavir for HIV prevention. See ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women [Protocol]. N Engl J Med. 2024:1-672. Bekker LG, Das M, Abdool Karim Q, et al ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. HIV prophylaxis drugs are effective at preventing future ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001.
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Women. July 28, 2025. Tap to unmute. Your browser can't play this video.
Channel @NationalHIVPrEPCurriculum! Recently Added. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. LG Bekker et al. No participants receiving twice-yearly lenacapavir acquired ...
... Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral ... Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
AfroCom: It's your one-stop super-app for connecting, sharing, and building with the global Afro-community.
ACCP HIV PRN. 519 次赞. The HIV PRN offers members the opportunity to collaborate and discuss the management of patients with HIV through transitions of...
Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7371Me gusta. 375Comentarios. 2789Veces compartido.
Quellen: Bekker et al.; N Engl J Med 2024; DOI: 10.1056/NEJMoa2407001 Kelley et al.; N Engl J Med 2024; DOI: 10.1056/NEJMoa2411858 https://www.science. org ...
doi: 10.1056/NEJMcp0904189. 3. Occupational Exposure to HIV in Health ... doi: 10.1056/NEJMoa2407001. 6. Viral Infections Associated With Injection ...
Referencia: DOI 10.1056/NEJMoa2407001 #. 50K · Dr. Parra será que si me hacen la diálisis y es el final de mi. 632.1K · #urgencias #choque #tac #craneo ...
Thomas MC, Edwards CJ, Dunlap A. 2025;392(5):401–13. protocol. Improved tolerability has. Practice patterns for N-acetylcysteine doi:10.1056/NEJMoa2407001 also ...
2024;391(13):1179–1192. Geneva: World Health Organization; 2024. https://doi.org/10.1056/NEJMoa2407001 20. Nel A, Van Niekerk N, Van Baelen B, et al. Safety ...
yearly lenacapavir or Daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179-92. doi: 10.1056/NEJMoa2407001. 6. Kelley CF, Acevedo- ...
https://www.nejm. org/doi/full/10.1056/NEJMoa2407001 Der Vorteil ggü. der täglichen Tabletteneinnahme der Prep ist kein medizinischer sondern allein die ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N ...
org/doi/full/10.1056/NEJMoa2407001 . 3. PURPOSE 2 Trial Data, Gilead Sciences Clinical Trials - https://www.gilead.com/purpose-trials . 4. WHO Statement on ...
... 10.1056/NEJMoa2407001. PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858. Créditos dos vídeos: Canal Wion (YT) #yeztugo #lenacapavir #ciencia ...
Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7327Likes. 377Comments. 2781Shares. genzattending. GenZ MD ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 Créditos dos vídeos: Canal Wion (YT) #yeztugo #lenacapavir #ciencia ...
Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7352Beğeniler. 374Yorumlar. 2783Paylaşımlar. 328 Likes, 28 ...
Referencia: DOI: 10.1056/NEJMoa2410819 #salud #medicina #diabetes. ... Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic ...
doi: 10.1056/NEJMoa2407001. pmid:39046157. 9. Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV preexposure prophylaxis with ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who- recommends-injectable-lenacapavir-for-hiv- prevention - https://www.nejm. org/doi/full ...
pdf - https://www.nejm. org/doi/10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who- recommends-injectable-lenacapavir-for-hiv- prevention ...
pdf - https://www.nejm. org/doi/10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who- recommends-injectable-lenacapavir-for-hiv- prevention ...
#drdiego #noticias #salud Fuente: DOI: 10.1056/NEJMoa2407001 Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7297Me gusta. 376Comentarios. 2779 ...
New England Journal of Medicine, 391(7), 648-659. DOI: 10.1056/NEJMoa2407001. Erythritol Ingestion Increases Platelet Reactivity and Thrombosis Potential in ...
doi: 10.1056/NEJMoa2407001. Online ahead of print. FULL T XT LINKS. Twice-Yearly Lenacapavir or Daily F/TAF for HIV NEJM FULLTEXT. Prevention in Cisgender ...
Watch to see how this drug is set to change the HIV prevention landscape. Original publication: https://www.nejm. org/doi/full/10.1056/NEJMoa2407001 Gilead ...
... 10.1056/NEJMoa2407001 in cui un farmaco (Lenacapavir) somministrato come iniezione due volte all'anno ha avuto risultati migliori che la classica PrEP ...
DOI: 10.1056/NEJMoa2407001. WHO report on HIV drug resistance – Rising dolutegravir resistance and implications for global care standards. 27 Apr, 2024 | 16 ...
DOI: 10.1056/NEJMoa2407001. Phase 3 RCT: Butantan-DV Dengue Vaccine is Safe and Shows 67.3% Efficacy Over 3.7 Years in Participants Aged 2–59 Years – Lancet ...
DOI: 10.1056/NEJMoa2407001. Erythritol Ingestion Increases Platelet Reactivity and Thrombosis Potential in Healthy Adults – Arterioscler Thromb Vasc Biol. 10 ...
doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. Now · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy · Consumer ...
doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. 5 hours ago. OCR. FDA APPROVED I New FDA FDA-approved HIV drug blocks infections for six ...
2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. 1 day ago · thedoctorasky's profile picture. thedoctorasky. •.
Source for these data is Bekker at al., NEJM 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2407001) @samandtifftalkscience · #science ...
... ;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. 9 hours ago · thedoctorasky's profile picture · thedoctorasky. •. Follow.
doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. Now · Sign up • Instagram · Meta · About · Blog · Jobs · Help · API · Privacy · Consumer ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
... in Cisgender Women. N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. Now · thedoctorasky. •. Follow.
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
https://doi.org/10.1056/NEJMoa2407001 PMID: 39046157. 4. Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, et ...
... 10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse ...
doi: 10.1056/NEJMoa2407001. pmid:39046157. 4. Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, et al. Twice ...
... 10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse ...
... 10.1056/NEJMra1905136) montrent qu'alterner périodes d ... Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858 ...
Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7372Likes. 375Comments. 2789Shares.
Source for these data is Bekker at al., NEJM 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2407001) @samandtifftalkscience · #science ...
Source for these data is Bekker at al., NEJM 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2407001) @samandtifftalkscience · #science ...
#drdiego #noticias #salud Fuente: DOI: 10.1056/NEJMoa2407001 Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7349Me gusta. 373 ...
Fuente: DOI: 10.1056/NEJMoa2407001. Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7344Likes. 373Comments. 2783Shares.
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 Créditos dos vídeos: Canal Wion (YT) #yeztugo ...
... ;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. PMID: 39046157. more. 18 hours ago · thedoctorasky's profile picture. thedoctorasky. •. Follow.
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women . N Engl J Med. 2024. ;. 391. : 1179. –. 92 . Google ...
Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391( ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. https://www.nejm.org/doi/full/10.1056/NEJMoa2407001; Descovy ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med 2024;391(13):1179-92. [PMID: 39046157] https ...
... 10.1056/NEJMoa2407001) veröffentlicht und heute auf der Welt-Aids-Konferenz in München (22. bis 26. Juli) vorgestellt. Gilead kündigte ein ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
... 10.1056/NEJMoa2407001 2️⃣ PURPOSE-2 Trial: https://www.nejm.org/doi/10.1056/NEJMoa2411858 #HIVPrevention #HIVPrEP #Yeztugo #Lenacapavir ...
Accessed July 8, 2025. 4. Bekker LG, Das M, Abdool Karim Q, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in. Cisgender ...
Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N ...
... 10.1056/NEJMoa2407001 2. https://www.nejm.org/doi/full/10.1056/NEJMoa2506549 3. https://www.thelancet.com/journals/lancet/article/PIIS0140 ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 Créditos dos vídeos: Canal Wion (YT) #yeztugo ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024;391(13):1179-1192. [PMID:39046157]. Comment ...
... yearly lenacapavir acquired HIV infection, and HIV incidence with lenacapavir ... Twice-yearly lenacapavir or daily F/TAF for HIV prevention in.
https://doi.org/10.1056/NEJMoa2407001 PMID: 39046157. 9. Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, et al. HIV preexposure ...
Source for these data is Bekker at al., NEJM 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2407001) ... 10.1056/NEJMoa2511774 2. https ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med 2024; 391:1179 DOI: 10.1056/NEJMoa2407001. Kelley ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who ... org/doi/full/10.1056/NEJMoa2411858. May be an image of medicine ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who ... org/doi/full/10.1056/NEJMoa2411858. May be an image of medicine ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who- recommends-injectable-lenacapavir-for-hiv- prevention - https://www ...
#drdiego #noticias #salud Fuente: DOI: 10.1056/NEJMoa2407001 Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7254Likes. 374 ...
#drdiego #noticias #salud Fuente: DOI: 10.1056/NEJMoa2407001 Fuente 2: DOI: 10.1056/NEJMoa2411858. Epic News - DM Production. 7301Me gusta. 376 ...
https://www.nejm.org/doi/10.1056/NEJMoa2407001 . https://www.nejm.org/doi/10.1056/NEJMoa2411858. more. View all 8 comments. 4 days ago.
... کارآزماییها : https://www.nejm.org/doi/10.1056/NEJMoa2407001 . https://www.nejm.org/doi/10.1056/NEJMoa2411858".
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. The New England journal of medicine, 391(13), 1179–1192 ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
, 2024, 391, 1179 (DOI: 10.1056/NEJMoa2407001). 2. C F Kelley et al, N. Engl. J. Med., 2024, 392, 1261 (DOI: 10.1056/NEJMoa2411858).
2. Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:-92. doi: 10.1056/NEJMoa2407001. pmid ...
... hiv; Bekker LG, Das M, Karim QA, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391 ...
#drdiego #noticias #salud Fuente: DOI: 10.1056/NEJMoa2407001 Fuente 2: DOI: 10.1056/NEJMoa2411858. Aprobación de lenacapavir para la ...
doi:10.1056/NEJMoa2407001; 5. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender ...
doi:10.1056/NEJMoa2407001. 5. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender ...
2024;doi:10.1056/NEJMoa2407001. Gilead signs royalty-free voluntary licensing agreements with six generic manufacturers to increase access ...
... 10.1056/NEJMoa2407001. PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858. Créditos dos vídeos: Canal Wion (YT) #yeztugo ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
... 10.1056/NEJMoa2407001) #microbiology #infectiousdisease #medicine #antibiotics #antimicrobials #infection #doctor #hospital #pharmacy ...
Bekker et al.: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1 trial) https://nej. md/3zRElVj ...
doi:10.1056/NEJMoa2407001. Online ahead of print. Cespedes M, Das M, Hojilla JC, et al. Proactive strategies to optimize engagement of Black ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
doi:10.1056/NEJMoa2407001. 15. Study of lenacapavir for HIV pre-exposure prophylaxis in people who are at risk for HIV infection (PURPOSE 2) ...
DOI: 10.1056/NEJMoa2407001. Epub 24 jul. 2024. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39046157/. Acesso em: 27 mar. 2025. UNAIDS ...
... 10.1056/NEJMoa2407001. Image Credits: National Institute of Allergy and Infectious Diseases. Keywords: HIV, lenacapavir, drug resistance ...
9. Bekker LG, Das M, Abdool Karim Q, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med ...
org/doi/full/10.1056/NEJMoa2407001. [9]https://www.nejm.org/doi/10.1056/NEJMoa2411858. [10]https://www.nejm.org/doi/full/10.1056/NEJMoa2101016.
doi:10.1056/NEJMoa2407001; Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN ...
... 10.1056/NEJMoa2407001 · "Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons", The New England Journal of Medicine ...
-G. Bekker et al., “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women,” N. Engl. J. Med ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who ... org/doi/full/10.1056/NEJMoa2411858. May be an image of medicine ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. ... Bekker, L.G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J.
... 10.1056/NEJMoa2407001 ). La presenza di ben 10 atomi di fluoro nella struttura del Lenacapavir che, dal punti di vista del chimico ...
... 10.1056/NEJMoa2407001 其它「入圍佳作」的科學進展包括： ⭕借由調控免疫細胞來治療自體免疫疾病的新策略https://www.nejm.org/doi/full/10.1056 ...
doi: 10.1056/NEJMoa2407001. PMID: 39046157. No photo description available. 1 reaction ·. 1 comment. ·. 1 share. The Learning Loop. 18w · Public ...
... 10.1056/NEJMoa2407001 其它「入圍佳作」的科學進展包括： ⭕借由調控免疫細胞來治療自體免疫疾病的新策略https://www.nejm.org/doi/full/10.1056 ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med 2024; Jul 24. doi: 10.1056/NEJMoa2407001 ...
... ://www.nejm. org/doi/full/10.1056/NEJMoa2407001. nejm.org. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in. 11 mos. 1. Other posts.
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 No site da Gilead, há os comunicados a imprensa que ...
... 10.1056/NEJMoa2407001 PURPOSE 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2411858 Créditos dos vídeos: Canal Wion (YT) #yeztugo ...
Bekker et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N. Engl. J. Med. (2024). R.M. Grant et al ...
Kigozi, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N. Engl. J. Med. (2024). Published online July ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender ...
... accessing medical and social stigma when taking HIV medication: https://www.nejm.org/doi/full/10.1056/NEJMoa2407001 · More replies. [deleted].
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who- recommends-injectable-lenacapavir-for-hiv- prevention - https://www ...
Very glad to see the encouraging development in #HIV prevention highlighted by The Lancet. However, any medical innovation is only as good ...
... Twice-Yearly Lenacapavir, a Game Changer in Ending the AIDS ... Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
世紀病毒—愛滋病預防的重大突破#結論： ✓NEJM: 隨機試驗顯示：在一年注射兩次lenacapavir女性中，沒有新發生任何愛滋病毒感染✓NEJM評論： 1. lenacapavir ...
世紀病毒—愛滋病預防的重大突破#結論： ✓NEJM: 隨機試驗顯示：在一年注射兩次lenacapavir女性中，沒有新發生任何愛滋病毒感染✓NEJM評論： 1. lenacapavir ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024 Jul 24. doi: 10.1056/NEJMoa2407001 ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine. 0(0). Link. From the ...
org/10.1056/NEJMoa2407001. 《中国科学报》 (2024-08-01 第2版国际). 打印 发E-mail给：. 以下评论只代表网友个人观点，不代表科学网观点。 相关新闻 ...
org/10.1056/NEJMoa2407001. 特别声明：本文为网易自媒体平台“网易号”作者上传并发布，仅代表该作者观点。网易仅提供信息发布平台。 Notice: The ...
https://www.nejm. org/doi/full/10.1056/NEJMoa2407001. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women |.
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women: Interim analysis results from the PURPOSE 1 study. AIDS 2024.
... 10.1056/NEJMoa2407001 #DüzenLaboratuvarı #HIV #AIDS #EnfeksiyonHastalıkları #HalkSağlığı #SağlıkBilgileri | Facebook. Log in. Facebook. No ...
... 10.1056/NEJMoa2407001 #DüzenLaboratuvarı #HIV #AIDS #EnfeksiyonHastalıkları #HalkSağlığı #SağlıkBilgileri | Facebook. Log in. Facebook. No ...
... /doi/full/10.1056/NEJMoa2407001 #DüzenLaboratuvarı #HIV #AIDS #EnfeksiyonHastalıkları #HalkSağlığı #SağlıkBilgileri".
org/doi/full/10.1056/NEJMoa2407001 2.https://clinicaltrials. gov/study/NCT04994509 3.https://www.gilead.com/news-and- press/press-room/press ...
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024. doi:10.1056/NEJMoa2407001. 2. Gilead. Full ...
https://www.nejm.org/doi/abs/10.1056/NEJMoa2407001. From the linked article: 'Miracle' new anti-HIV jab could revolutionise virus prevention.
Close menu. Study: https://www.nejm.org/doi/abs/10.1056/NEJMoa2407001 · Like · Reply · 5 Reactions 6 Reactions. Professor Erwin Loh, graphic.
F/TAF: Emtricitabine + Tenofovir Alafenamide Fumarate (Descovy). Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
doi: 10.1056/NEJMoa2407001. Aimee Cunningham. About Aimee Cunningham · E-mail · X. Aimee Cunningham is the biomedical writer. She has a master's ...
... 10.1056/NEJMoa2407001. Secondary Source. New England Journal of Medicine. Source Reference: Walensky RP, Baden LR "The real PURPOSE of PrEP ...
DOI: 10.1056/NEJMoa2407001. Journal information: New England Journal of Medicine. © 2024 The Associated Press. All rights reserved. This ...
2024;doi:10.1056/NEJMoa2407001. Updated statement on global access planning for lenacapavir for HIV prevention. https://www.gilead.com/news ...
Die Ergebnisse wurden im New England Journal of Medicine (NEJM) (DOI: 10.1056/NEJMoa2407001) veröffentlicht und heute auf der Welt-Aids ...
Injektionsbehanlding två gånger om året med Sunlenca (lenakapavir) var mycket effektivt som preexpositionsprofylax för unga kvinnor.
... The study is published in the New England Journal of Medicine here https://www.nejm.org/doi/full/10.1056/NEJMoa2407001 · PlasmidDNA. • 1y ago.
DOI: 10.1056/NEJMoa2407001. loading... Frag die KI. Die experimentelle KI von PZ und PTA-Forum. Die experimentelle KI von PZ und PTA-Forum. Die ...
DOI: 10.1056/NEJMoa2407001. loading... Frag die KI. Die experimentelle KI von PZ und PTA-Forum. Die experimentelle KI von PZ und PTA-Forum. Die ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. Authors: Linda-Gail Bekker, M.B., Ch.B., Ph.D. https://orcid ...
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. L.-G. Bekker, M. Das, Q. Abdool Karim, K. Ahmed, J. Batting, W ...
... 10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025-who ... org/doi/full/10.1056/NEJMoa2411858. May be an image of medicine ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
org/doi/full/10.1056/NEJMoa2407001 Der Vorteil ggü. der täglichen Tabletteneinnahme der Prep ist kein medizinischer sondern allein die ...
the votes are in Congratulations Marisa Brizzi, incoming Chair-Elect and David Cluck, our incoming secretary/treasurer We look forward ...
gov/drugsatfda_docs/label/2025/220020s000lbl.pdf - https://www.nejm.org/doi/10.1056/NEJMoa2407001 - https://www.who.int/news/item/14-07-2025 ...
Joseph's University Medical Center in Paterson, NJ (serving ~1,100 persons with HIV), and recently became the Director of Diverse Scholar ...
Kicking off our member accomplishment highlights with Gabriella Douglass and Pranav Amin! This RPD and resident duo were featured in AJHP ...
doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV Prevention in Men and Gender ...
DOI: 10.1056/NEJMoa2407001 • Kelley, C. F., Acevedo-Quiñones, M., et al. (2024). Twice-yearly lenacapavir for HIV prevention in men and ...
org/doi/10.1056/NEJMoa2407001 2️⃣ PURPOSE-2 Trial: https://www.nejm. org/doi/10.1056/NEJMoa2411858 #HIVPrevention #HIVPrEP #Yeztugo ...
HIV PRN MEMBER SPOTLIGHT Jessica L. Adams, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice at the Philadelphia College of ...
PGY 2+3 residency: UIC College of Pharmacy, Department of Pharmacy Practice, Chicago IL Length of membership with HIV PRN: I joined in 2015 ...
2024;391(13): 1179-1192. doi:10.1056/NEJMoa2407001 - Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice- Yearly Lenacapavir for HIV ...
doi:10.1056/NEJMoa2407001; 5. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender ...
doi: 10.1056/NEJMoa2407001 PMID: 39046157.
Y
SH
MM
TB
PD
GV
EP